ATE501726T1 - Zusammensetzung mit immunogenen mikroteilchen - Google Patents

Zusammensetzung mit immunogenen mikroteilchen

Info

Publication number
ATE501726T1
ATE501726T1 AT01966829T AT01966829T ATE501726T1 AT E501726 T1 ATE501726 T1 AT E501726T1 AT 01966829 T AT01966829 T AT 01966829T AT 01966829 T AT01966829 T AT 01966829T AT E501726 T1 ATE501726 T1 AT E501726T1
Authority
AT
Austria
Prior art keywords
microparticles
composition
immunogenic microparticles
provides
immunogenic
Prior art date
Application number
AT01966829T
Other languages
English (en)
Inventor
Magdalena Plebanski
Original Assignee
Austin Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR4888A external-priority patent/AUPR488801A0/en
Priority claimed from AUPR4962A external-priority patent/AUPR496201A0/en
Application filed by Austin Research Inst filed Critical Austin Research Inst
Application granted granted Critical
Publication of ATE501726T1 publication Critical patent/ATE501726T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT01966829T 2000-09-14 2001-09-14 Zusammensetzung mit immunogenen mikroteilchen ATE501726T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPR0117A AUPR011700A0 (en) 2000-09-14 2000-09-14 Composition comprising immunogenic virus sized particles (VSP)
AUPR4888A AUPR488801A0 (en) 2001-05-10 2001-05-10 Composition comprising immunogenic virus sized particles (vsp)
AUPR4962A AUPR496201A0 (en) 2001-05-14 2001-05-14 Composition comprising immunogenic virus sized particles (VSP)
PCT/AU2001/001160 WO2002022164A1 (en) 2000-09-14 2001-09-14 Composition comprising immunogenic microparticles

Publications (1)

Publication Number Publication Date
ATE501726T1 true ATE501726T1 (de) 2011-04-15

Family

ID=27158243

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01966829T ATE501726T1 (de) 2000-09-14 2001-09-14 Zusammensetzung mit immunogenen mikroteilchen

Country Status (15)

Country Link
US (3) US20040014708A1 (de)
EP (1) EP1326633B1 (de)
JP (1) JP5198712B2 (de)
KR (1) KR20030055262A (de)
CN (1) CN100446811C (de)
AT (1) ATE501726T1 (de)
AU (1) AUPR011700A0 (de)
CA (1) CA2422575C (de)
DE (1) DE60144240D1 (de)
DK (1) DK1326633T3 (de)
ES (1) ES2363735T3 (de)
IL (1) IL154913A0 (de)
NZ (2) NZ524843A (de)
PT (1) PT1326633E (de)
WO (1) WO2002022164A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
FR2844514B1 (fr) 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
DK1623017T3 (da) * 2003-05-08 2011-01-10 Life Technologies Corp Frembringelse og isolering af antigenspecifikke T-celler
JPWO2005053740A1 (ja) * 2003-12-02 2007-06-28 株式会社 バイオマトリックス研究所 免疫増強剤およびこれを用いた強化抗原
WO2006012695A1 (en) * 2004-08-04 2006-02-09 Panvax Limited An immunogenic composition
CN101247826A (zh) * 2005-08-25 2008-08-20 大鹏药品工业株式会社 固定或内包t细胞识别抗原表位肽的生物降解性纳米粒子
WO2008150276A2 (en) * 2006-09-26 2008-12-11 The Board Of Regents Of The University Of Texas System Virus coated nanoparticles and uses thereof
US9764012B2 (en) 2009-04-01 2017-09-19 University Of Miami Vaccine compositions and methods of use thereof
CA2762586C (en) * 2009-05-19 2018-06-19 University Of Miami Compositions, kits and methods for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity of biologics and drugs
CN106421743A (zh) * 2009-07-29 2017-02-22 贝恩德·赫尔穆特·阿达姆·雷姆 聚合物微粒及其用途
RS56157B1 (sr) 2010-11-05 2017-11-30 Novavax Inc Glikoproteinske čestice nalik virusu (vlp) besnila
US20120189700A1 (en) * 2011-01-19 2012-07-26 Zoraida Aguilar Nanoparticle Based Immunological Stimulation
JP6100762B2 (ja) 2011-06-02 2017-03-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 膜で被包されたナノ粒子および使用方法
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
WO2015021390A2 (en) 2013-08-08 2015-02-12 The Regents Of The University Of California Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis
CN106163504B (zh) 2014-03-20 2021-02-09 加利福尼亚大学董事会 水凝胶毒素-吸收或结合纳米颗粒
SG10201808867PA (en) 2014-04-07 2018-11-29 Minerva Biotechnologies Corp Anti-nme antibody
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
EP4140492A1 (de) 2015-04-21 2023-03-01 Enlivex Therapeutics Rdo Ltd Therapeutische gepoolte blutapoptotische zellpräparate und verwendungen davon
US10610493B2 (en) 2015-04-29 2020-04-07 The Regents Of The University Of California Detoxification using nanoparticles
MX2018002728A (es) 2015-09-03 2018-09-05 Novavax Inc Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
JP6884155B2 (ja) 2016-02-18 2021-06-09 エンリヴェックス セラピューティクス リミテッド 癌治療のための併用免疫療法及びサイトカイン制御療法
CN109200271B (zh) * 2018-11-14 2021-01-29 江南大学 一种蛋白质及其在调控巨噬细胞免疫功能方面的应用
WO2020257315A1 (en) * 2019-06-18 2020-12-24 Citranvi Biosciences, Llc Multiple antigen protein displayed adjuvant systems
WO2020257317A1 (en) * 2019-06-18 2020-12-24 Citranvi Biosciences, Llc Rationally engineered carrier proteins for vaccines
CN110339350A (zh) * 2019-07-25 2019-10-18 广州中科蓝华生物科技有限公司 一种抗肿瘤的联合用药物组合物及其应用
WO2021263227A2 (en) 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
EP4188437A4 (de) * 2020-07-31 2024-09-25 The Board of Trustees of the Leland Stanford Junior University Impfstoffzusammensetzungen und verfahren zur verwendung davon
WO2024097307A1 (en) * 2022-11-01 2024-05-10 Lupagen, Inc. Devices and methods for extracorporeal cell treatment

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK143689C (da) * 1975-03-20 1982-03-15 J Kreuter Fremgangsmaade til fremstilling af en adsorberet vaccine
US4035316A (en) * 1975-11-24 1977-07-12 California Institute Of Technology Cell specific, variable density, polymer microspheres
US4170685A (en) * 1976-03-29 1979-10-09 California Institute Of Technology Polyvinyl pyridine microspheres
US4157323A (en) * 1976-06-09 1979-06-05 California Institute Of Technology Metal containing polymeric functional microspheres
US4247434A (en) * 1978-12-29 1981-01-27 Lovelace Alan M Administrator Process for preparation of large-particle-size monodisperse
US4438239A (en) * 1981-03-30 1984-03-20 California Institute Of Technology Microsphere coated substrate containing reactive aldehyde groups
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4828984A (en) * 1986-04-11 1989-05-09 Flow Cytometry Standards Corporation Composition, synthesis and use of simulated cells
US6338853B1 (en) 1987-04-23 2002-01-15 Jean-Claude Bystryn Anti-cancer vaccine
US5002883A (en) * 1987-10-30 1991-03-26 Abbott Laboratories Covalent attachment of antibodies and antigens to solid phases using extended length heterobifunctional coupling agents
GB2237510B (en) 1989-11-04 1993-09-15 Danbiosyst Uk Small particle drug compositions for nasal administration
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
US5219577A (en) 1990-06-22 1993-06-15 The Regents Of The University Of California Biologically active composition having a nanocrystalline core
US5334394A (en) * 1990-06-22 1994-08-02 The Regents Of The University Of California Human immunodeficiency virus decoy
US5178882A (en) * 1990-06-22 1993-01-12 The Regents Of The University Of California Viral decoy vaccine
US5665582A (en) * 1990-10-29 1997-09-09 Dekalb Genetics Corp. Isolation of biological materials
US6129916A (en) * 1991-04-19 2000-10-10 Tanox, Inc. Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates
US5688761A (en) * 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
FR2695563B1 (fr) * 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
JPH08505625A (ja) * 1993-01-11 1996-06-18 ダナ−ファーバー キャンサー インスティチュート 細胞毒性ｔリンパ球応答の誘導
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
EP1181937A3 (de) * 1994-08-09 2004-02-04 Cytrx Corporation Nukleinsäure enthaltender Impfstoff, Impfstoff-adjuvans
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
DE69526260T2 (de) 1994-11-15 2002-10-17 Powderject Vaccines, Inc. Methode zur induktion der humoralen und zellulären immunantwort durch intrazelluläre zufuhr von peptidbeschichteten mikropartikeln
CA2207961A1 (en) 1995-01-05 1996-07-11 Robert J. Levy Surface-modified nanoparticles and method of making and using same
CA2227287A1 (en) * 1995-07-21 1997-02-06 Brown University Research Foundation A method for gene therapy using nucleic acid loaded polymeric microparticles
DE69712108T2 (de) * 1996-07-10 2002-12-12 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Ltd., Nottingham Gentherapiesystem zur zielung des endotheliums
US5789261A (en) * 1996-10-30 1998-08-04 Temple University Of The Commonwealth System Of Higher Education Solid phase immunoassay
AU747577B2 (en) 1997-01-30 2002-05-16 Novartis Vaccines And Diagnostics, Inc. Use of microparticles with adsorbed antigen to stimulate immune responses
ES2248914T3 (es) 1997-08-29 2006-03-16 Corixa Corporation Agentes bioactivos encapsulados de liberacion rapida que permiten inducir o potenciar una respuesta inmunitaria y metodos para utilizar los mismos.
US6001333A (en) 1997-09-12 1999-12-14 See; Jackie R. Methods of preparing micro encapsulated agents for use in the detection of tumors by CT imaging
US6475995B1 (en) 1998-01-16 2002-11-05 The Johns Hopkins University Oral delivery of nucleic acid vaccines by particulate complexes
SE9800615D0 (sv) 1998-02-27 1998-02-27 Ingvar Sjoeholm Mucosal microparticle conjugate vaccine
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
AU5441199A (en) 1998-09-01 2000-03-21 Elan Corporation, Plc Oral vaccine compositions
DE60013773T2 (de) * 1999-02-03 2005-11-10 Biosante Pharmaceuticals, Inc. Methoden zur Herstellung von therapeutischen Kalziumphosphat Partikeln
ATE407695T1 (de) 1999-02-09 2008-09-15 Riken Tumorimpfstoff
AU3730600A (en) * 1999-03-18 2000-10-04 Xiaojiang Chen Compositions preparations and uses of human papillomavirus l1 protein
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
JP2003501379A (ja) 1999-06-02 2003-01-14 ナノファーマ アーゲー ガン治療のための薬剤を充填したナノパーティクルの使用
EP1118331A1 (de) * 2000-01-21 2001-07-25 I.D.M. Immuno-Designed Molecules Verfahren zur Verstärkung der Präsentation exogener Antigene durch menschlische Antigen-präsentierende Zellen und opsonisierte Mikropartikelkomplexe zur Anwendung dieser Methode
US20050181063A1 (en) 2000-03-22 2005-08-18 Alpar Hazire O. Pharmaceutical composition for administration to mucosal surfaces
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
FR2859909B1 (fr) 2003-09-22 2007-09-07 Biomerieux Sa Procede de preparation de microparticules bioresorbables, microparticules obtenues et utilisation
US20070275007A1 (en) 2003-11-05 2007-11-29 The Government Of The United States Of America, Represented By The Secretary Of Health And Human S Carbohydrate Antigen-Nanoparticle Conjugates and Uses Thereof as Antimetastatic Agents in Treating Cancer
AU2004314706A1 (en) 2003-12-11 2005-08-11 University Of Miami Immunotherapy compositions, method of making and method of use thereof
ES2564241T3 (es) 2005-12-02 2016-03-21 Glaxosmithkline Biologicals Sa Nanopartículas para su uso en composiciones inmunogénicas
US8021689B2 (en) 2006-02-21 2011-09-20 Ecole Polytechnique Federale de Lausanne (“EPFL”) Nanoparticles for immunotherapy
EP1991204A2 (de) 2006-02-24 2008-11-19 Novartis AG Mikropartikel mit biologisch abbaubarem polymer und kationischem polysaccharid zur verwendung für immunogene zusammensetzungen
JP2009541281A (ja) 2006-06-20 2009-11-26 シーエムピー セラピューティクス リミテッド キチンマイクロ粒子を含む組成物およびそれらの医学的使用
WO2008022253A2 (en) 2006-08-16 2008-02-21 Temple University-Of The Commonwealth System Of Higher Education An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions
WO2008082439A2 (en) 2006-08-28 2008-07-10 Duke University Antigen specific nanoparticles
AT504160A1 (de) 2006-09-11 2008-03-15 Ralf Dr Kircheis Verwendung einer mehrkomponenten-tumorvakzine
WO2008118861A2 (en) 2007-03-23 2008-10-02 The University Of North Carolina At Chapel Hill Discrete size and shape specific organic nanoparticles designed to elicit an immune response
EP3424525A1 (de) 2007-10-12 2019-01-09 Massachusetts Institute Of Technology Impfstoffnanotechnologie
US9107858B2 (en) 2007-12-05 2015-08-18 Wisconsin Alumni Research Foundation Dendritic cell targeting compositions and uses thereof
EP2250189A4 (de) 2008-02-26 2012-07-04 Univ California Gylcopeptide sowie verfahren zu ihrer herstellung und verwendung
CA2750098A1 (en) 2009-01-20 2010-07-29 Myelin Repair Foundation, Inc. Compositions and methods for induction of antigen-specific tolerance

Also Published As

Publication number Publication date
JP5198712B2 (ja) 2013-05-15
US20040014708A1 (en) 2004-01-22
NZ535851A (en) 2006-04-28
IL154913A0 (en) 2003-10-31
AUPR011700A0 (en) 2000-10-05
EP1326633A4 (de) 2006-05-24
US20100136043A1 (en) 2010-06-03
CN1630531A (zh) 2005-06-22
ES2363735T3 (es) 2011-08-12
EP1326633B1 (de) 2011-03-16
CA2422575A1 (en) 2002-03-21
US20120082725A1 (en) 2012-04-05
CN100446811C (zh) 2008-12-31
DE60144240D1 (de) 2011-04-28
US8287877B2 (en) 2012-10-16
DK1326633T3 (da) 2011-07-04
WO2002022164A1 (en) 2002-03-21
KR20030055262A (ko) 2003-07-02
PT1326633E (pt) 2011-06-29
NZ524843A (en) 2004-11-26
CA2422575C (en) 2015-04-28
JP2004507566A (ja) 2004-03-11
EP1326633A1 (de) 2003-07-16
US8846026B2 (en) 2014-09-30

Similar Documents

Publication Publication Date Title
DE60144240D1 (de) Zusammensetzung mit immunogenen mikroteilchen
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
WO2005037190A3 (en) Multiplex vaccines
DK1635863T3 (da) Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål
TR200102739T2 (tr) Aşı
EP1594536A4 (de) Adjuvante influenza-vakzine
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
NO20015073L (no) Vaksiner
NZ596870A (en) Vaccine compositions comprising a saponin adjuvant
WO2004032829A3 (en) Immunostimulatory compositions and methods of stimulating an immune response
NO20023935L (no) Ny, ikke-antigen, mukosal adjuvansformulering som modulerer effektene av substanser inkludert vaksineantigener, i kontakt medmukosale kroppsoverflater
DE60136563D1 (de) Salmonella vakzine
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
WO2003053338A3 (en) Novel chimeric rev, tat, and nef antigens
WO2007078879A3 (en) Lipopeptide compositions and methods of use thereof
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
AU2002342949A1 (en) Vaccine composition comprising at least two valences, one with enhanced adjuvant and not the other
WO2002032455A3 (en) Vaccine
DE60036705D1 (de) Adjuvanskombinationen zur immunisierung und vakzine
HK1075842A (en) Nanoemulsion vaccines
IL193391A0 (en) Influenza antigens, vaccine compositions, and related methods

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1326633

Country of ref document: EP